{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T05:58:37Z","timestamp":1778047117064,"version":"3.51.4"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T00:00:00Z","timestamp":1751414400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T00:00:00Z","timestamp":1751414400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-04595-z","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T23:12:39Z","timestamp":1751411559000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Risk factors and reasons for romosozumab nonadherence in a case-control study"],"prefix":"10.1038","volume":"15","author":[{"given":"Ting-Chien","family":"Tsai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yun-Shan","family":"Yen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chang-Hao","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ya-Chi","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-Sian","family":"Ding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chen-Hao","family":"Chiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheng-Yi","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,2]]},"reference":[{"key":"4595_CR1","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.bone.2017.04.005","volume":"101","author":"RW Boyce","year":"2017","unstructured":"Boyce, R. W., Niu, Q. T. & Ominsky, M. S. Kinetic reconstruction reveals time-dependent effects of Romosozumab on bone formation and osteoblast function in vertebral cancellous and cortical bone in cynomolgus monkeys. Bone 101, 77\u201387. https:\/\/doi.org\/10.1016\/j.bone.2017.04.005 (2017).","journal-title":"Bone"},{"key":"4595_CR2","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1002\/jbmr.3038","volume":"32","author":"SW Kim","year":"2017","unstructured":"Kim, S. W. et al. Sclerostin antibody administration converts bone lining cells into active osteoblasts. J. Bone Min. Res. 32, 892\u2013901. https:\/\/doi.org\/10.1002\/jbmr.3038 (2017).","journal-title":"J. Bone Min. Res."},{"key":"4595_CR3","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1056\/NEJMoa1305224","volume":"370","author":"MR McClung","year":"2014","unstructured":"McClung, M. R. et al. Romosozumab in postmenopausal women with low bone mineral density. N Engl. J. Med. 370, 412\u2013420. https:\/\/doi.org\/10.1056\/NEJMoa1305224 (2014).","journal-title":"N Engl. J. Med."},{"key":"4595_CR4","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1002\/jbmr.2482","volume":"30","author":"P Nioi","year":"2015","unstructured":"Nioi, P. et al. Transcriptional profiling of laser capture microdissected subpopulations of the osteoblast lineage provides insight into the early response to sclerostin antibody in rats. J. Bone Min. Res. 30, 1457\u20131467. https:\/\/doi.org\/10.1002\/jbmr.2482 (2015).","journal-title":"J. Bone Min. Res."},{"key":"4595_CR5","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.bone.2016.10.019","volume":"96","author":"MS Ominsky","year":"2017","unstructured":"Ominsky, M. S., Boyce, R. W., Li, X. & Ke, H. Z. Effects of sclerostin antibodies in animal models of osteoporosis. Bone 96, 63\u201375. https:\/\/doi.org\/10.1016\/j.bone.2016.10.019 (2017).","journal-title":"Bone"},{"key":"4595_CR6","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.bone.2015.08.007","volume":"81","author":"MS Ominsky","year":"2015","unstructured":"Ominsky, M. S. et al. Differential Temporal effects of sclerostin antibody and parathyroid hormone on cancellous and cortical bone and quantitative differences in effects on the osteoblast lineage in young intact rats. Bone 81, 380\u2013391. https:\/\/doi.org\/10.1016\/j.bone.2015.08.007 (2015).","journal-title":"Bone"},{"key":"4595_CR7","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1002\/jbmr.2152","volume":"29","author":"MS Ominsky","year":"2014","unstructured":"Ominsky, M. S., Niu, Q. T., Li, C., Li, X. & Ke, H. Z. Tissue-level mechanisms responsible for the increase in bone formation and bone volume by sclerostin antibody. J. Bone Min. Res. 29, 1424\u20131430. https:\/\/doi.org\/10.1002\/jbmr.2152 (2014).","journal-title":"J. Bone Min. Res."},{"key":"4595_CR8","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1002\/jbmr.14","volume":"25","author":"MS Ominsky","year":"2010","unstructured":"Ominsky, M. S. et al. Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength. J. Bone Min. Res. 25, 948\u2013959. https:\/\/doi.org\/10.1002\/jbmr.14 (2010).","journal-title":"J. Bone Min. Res."},{"key":"4595_CR9","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.bone.2015.12.013","volume":"84","author":"S Taylor","year":"2016","unstructured":"Taylor, S. et al. Time-dependent cellular and transcriptional changes in the osteoblast lineage associated with sclerostin antibody treatment in ovariectomized rats. Bone 84, 148\u2013159. https:\/\/doi.org\/10.1016\/j.bone.2015.12.013 (2016).","journal-title":"Bone"},{"key":"4595_CR10","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1038\/nm.3074","volume":"19","author":"R Baron","year":"2013","unstructured":"Baron, R. & Kneissel, M. WNT signaling in bone homeostasis and disease: from human mutations to treatments. Nat. Med. 19, 179\u2013192. https:\/\/doi.org\/10.1038\/nm.3074 (2013).","journal-title":"Nat. Med."},{"key":"4595_CR11","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1177\/1759720x18775936","volume":"10","author":"ASK S\u00f8lling","year":"2018","unstructured":"S\u00f8lling, A. S. K., Harsl\u00f8f, T. & Langdahl, B. The clinical potential of Romosozumab for the prevention of fractures in postmenopausal women with osteoporosis. Ther. Adv. Musculoskelet. Dis. 10, 105\u2013115. https:\/\/doi.org\/10.1177\/1759720x18775936 (2018).","journal-title":"Ther. Adv. Musculoskelet. Dis."},{"key":"4595_CR12","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1002\/jbmr.173","volume":"26","author":"D Padhi","year":"2011","unstructured":"Padhi, D., Jang, G., Stouch, B., Fang, L. & Posvar, E. Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J. Bone Min. Res. 26, 19\u201326. https:\/\/doi.org\/10.1002\/jbmr.173 (2011).","journal-title":"J. Bone Min. Res."},{"key":"4595_CR13","doi-asserted-by":"publisher","first-page":"2437","DOI":"10.1007\/s00198-019-05146-9","volume":"30","author":"DL Kendler","year":"2019","unstructured":"Kendler, D. L. et al. Bone mineral density gains with a second 12-month course of Romosozumab therapy following placebo or denosumab. Osteoporos. Int. 30, 2437\u20132448. https:\/\/doi.org\/10.1007\/s00198-019-05146-9 (2019).","journal-title":"Osteoporos. Int."},{"key":"4595_CR14","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1002\/jbmr.3439","volume":"33","author":"F Cosman","year":"2018","unstructured":"Cosman, F. et al. Romosozumab FRAME study: A post hoc analysis of the role of regional background fracture risk on nonvertebral fracture outcome. J. Bone Min. Res. 33, 1407\u20131416. https:\/\/doi.org\/10.1002\/jbmr.3439 (2018).","journal-title":"J. Bone Min. Res."},{"key":"4595_CR15","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","volume":"377","author":"KG Saag","year":"2017","unstructured":"Saag, K. G. et al. Romosozumab or alendronate for fracture prevention in women with osteoporosis. N Engl. J. Med. 377, 1417\u20131427. https:\/\/doi.org\/10.1056\/NEJMoa1708322 (2017).","journal-title":"N Engl. J. Med."},{"key":"4595_CR16","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1016\/s0140-6736(17)31613-6","volume":"390","author":"BL Langdahl","year":"2017","unstructured":"Langdahl, B. L. et al. Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial. Lancet 390, 1585\u20131594. https:\/\/doi.org\/10.1016\/s0140-6736(17)31613-6 (2017).","journal-title":"Lancet"},{"key":"4595_CR17","doi-asserted-by":"publisher","first-page":"3183","DOI":"10.1210\/jc.2017-02163","volume":"103","author":"EM Lewiecki","year":"2018","unstructured":"Lewiecki, E. M. et al. A phase III randomized Placebo-Controlled trial to evaluate efficacy and safety of Romosozumab in men with osteoporosis. J. Clin. Endocrinol. Metab. 103, 3183\u20133193. https:\/\/doi.org\/10.1210\/jc.2017-02163 (2018).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"4595_CR18","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","volume":"375","author":"F Cosman","year":"2016","unstructured":"Cosman, F. et al. Romosozumab treatment in postmenopausal women with osteoporosis. N Engl. J. Med. 375, 1532\u20131543. https:\/\/doi.org\/10.1056\/NEJMoa1607948 (2016).","journal-title":"N Engl. J. Med."},{"key":"4595_CR19","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1037\/0278-6133.23.2.207","volume":"23","author":"MR DiMatteo","year":"2004","unstructured":"DiMatteo, M. R. Social support and patient adherence to medical treatment: a meta-analysis. Health Psychol. 23, 207\u2013218. https:\/\/doi.org\/10.1037\/0278-6133.23.2.207 (2004).","journal-title":"Health Psychol."},{"key":"4595_CR20","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/s0022-3999(99)00057-4","volume":"47","author":"R Horne","year":"1999","unstructured":"Horne, R. & Weinman, J. Patients\u2019 beliefs about prescribed medicines and their role in adherence to treatment in chronic physical illness. J. Psychosom. Res. 47, 555\u2013567. https:\/\/doi.org\/10.1016\/s0022-3999(99)00057-4 (1999).","journal-title":"J. Psychosom. Res."},{"key":"4595_CR21","doi-asserted-by":"publisher","unstructured":"Nieuwlaat, R. et al. Interventions for enhancing medication adherence. Cochrane Database Syst Rev. Cd000011, (2014). https:\/\/doi.org\/10.1002\/14651858.CD000011.pub4 (2014).","DOI":"10.1002\/14651858.CD000011.pub4"},{"key":"4595_CR22","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1056\/NEJMra050100","volume":"353","author":"L Osterberg","year":"2005","unstructured":"Osterberg, L. & Blaschke, T. Adherence to medication. N Engl. J. Med. 353, 487\u2013497. https:\/\/doi.org\/10.1056\/NEJMra050100 (2005).","journal-title":"N Engl. J. Med."},{"key":"4595_CR23","doi-asserted-by":"publisher","first-page":"2623","DOI":"10.1007\/s00198-018-4759-3","volume":"29","author":"CT Yeam","year":"2018","unstructured":"Yeam, C. T. et al. A systematic review of factors affecting medication adherence among patients with osteoporosis. Osteoporos. Int. 29, 2623\u20132637. https:\/\/doi.org\/10.1007\/s00198-018-4759-3 (2018).","journal-title":"Osteoporos. Int."},{"key":"4595_CR24","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1007\/s10461-009-9663-6","volume":"14","author":"AS Batavia","year":"2010","unstructured":"Batavia, A. S. et al. Adherence to antiretroviral therapy in patients participating in a graduated cost recovery program at an HIV care center in South India. AIDS Behav. 14, 794\u2013798. https:\/\/doi.org\/10.1007\/s10461-009-9663-6 (2010).","journal-title":"AIDS Behav."},{"key":"4595_CR25","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1016\/j.juro.2009.11.026","volume":"183","author":"CL Sears","year":"2010","unstructured":"Sears, C. L., Lewis, C., Noel, K., Albright, T. S. & Fischer, J. R. Overactive bladder medication adherence when medication is free to patients. J. Urol. 183, 1077\u20131081. https:\/\/doi.org\/10.1016\/j.juro.2009.11.026 (2010).","journal-title":"J. Urol."},{"key":"4595_CR26","first-page":"2","volume":"13","author":"H Aziz","year":"2018","unstructured":"Aziz, H. et al. A comparison of medication adherence between subsidized and self-paying patients in Malaysia. Malays Fam Physician. 13, 2\u20139 (2018).","journal-title":"Malays Fam Physician"},{"key":"4595_CR27","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1007\/s00774-013-0424-2","volume":"31","author":"SF Yu","year":"2013","unstructured":"Yu, S. F. et al. Non-adherence to anti-osteoporotic medications in taiwan: physician specialty makes a difference. J. Bone Min. Metab. 31, 351\u2013359. https:\/\/doi.org\/10.1007\/s00774-013-0424-2 (2013).","journal-title":"J. Bone Min. Metab."},{"key":"4595_CR28","doi-asserted-by":"publisher","first-page":"2079","DOI":"10.1007\/s00198-012-2221-5","volume":"24","author":"C Hansen","year":"2013","unstructured":"Hansen, C., Pedersen, B. D., Konradsen, H. & Abrahamsen, B. Anti-osteoporotic therapy in Denmark\u2013predictors and demographics of poor refill compliance and poor persistence. Osteoporos. Int. 24, 2079\u20132097. https:\/\/doi.org\/10.1007\/s00198-012-2221-5 (2013).","journal-title":"Osteoporos. Int."},{"key":"4595_CR29","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1186\/1471-2474-15-112","volume":"15","author":"H Yun","year":"2014","unstructured":"Yun, H. et al. Patterns and predictors of osteoporosis medication discontinuation and switching among medicare beneficiaries. BMC Musculoskelet. Disord. 15, 112. https:\/\/doi.org\/10.1186\/1471-2474-15-112 (2014).","journal-title":"BMC Musculoskelet. Disord"},{"key":"4595_CR30","doi-asserted-by":"publisher","unstructured":"Tanaka, I. et al. Adherence and persistence with once-daily teriparatide in japan: a retrospective, prescription database, cohort study. J. Osteoporos. 2013 (654218). https:\/\/doi.org\/10.1155\/2013\/654218 (2013).","DOI":"10.1155\/2013\/654218"},{"key":"4595_CR31","doi-asserted-by":"publisher","first-page":"11784","DOI":"10.1038\/s41598-017-10899-6","volume":"7","author":"A Garc\u00eda-Sempere","year":"2017","unstructured":"Garc\u00eda-Sempere, A. et al. Primary and secondary non-adherence to osteoporotic medications after hip fracture in spain. The PREV2FO population-based retrospective cohort study. Sci. Rep. 7, 11784. https:\/\/doi.org\/10.1038\/s41598-017-10899-6 (2017).","journal-title":"Sci. Rep."},{"key":"4595_CR32","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1007\/s00198-008-0618-y","volume":"19","author":"H Ideguchi","year":"2008","unstructured":"Ideguchi, H., Ohno, S., Takase, K., Ueda, A. & Ishigatsubo, Y. Outcomes after switching from one bisphosphonate to another in 146 patients at a single university hospital. Osteoporos. Int. 19, 1777\u20131783. https:\/\/doi.org\/10.1007\/s00198-008-0618-y (2008).","journal-title":"Osteoporos. Int."},{"key":"4595_CR33","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1002\/acr.21638","volume":"64","author":"JR Curtis","year":"2012","unstructured":"Curtis, J. R., Yun, H., Matthews, R., Saag, K. G. & Delzell, E. Adherence with intravenous zoledronate and intravenous ibandronate in the united States medicare population. Arthritis Care Res. (Hoboken). 64, 1054\u20131060. https:\/\/doi.org\/10.1002\/acr.21638 (2012).","journal-title":"Arthritis Care Res. (Hoboken)"},{"key":"4595_CR34","first-page":"e138","volume":"20","author":"M Casula","year":"2014","unstructured":"Casula, M. et al. Assessment and potential determinants of compliance and persistence to antiosteoporosis therapy in Italy. Am. J. Manag Care. 20, e138\u2013145 (2014).","journal-title":"Am. J. Manag Care"},{"key":"4595_CR35","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1007\/s00198-011-1881-x","volume":"23","author":"YK Lee","year":"2012","unstructured":"Lee, Y. K., Nho, J. H., Ha, Y. C. & Koo, K. H. Persistence with intravenous zoledronate in elderly patients with osteoporosis. Osteoporos. Int. 23, 2329\u20132333. https:\/\/doi.org\/10.1007\/s00198-011-1881-x (2012).","journal-title":"Osteoporos. Int."},{"key":"4595_CR36","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1007\/s00198-008-0795-8","volume":"20","author":"O Sheehy","year":"2009","unstructured":"Sheehy, O., Kindundu, C. M., Barbeau, M. & LeLorier, J. Differences in persistence among different weekly oral bisphosphonate medications. Osteoporos. Int. 20, 1369\u20131376. https:\/\/doi.org\/10.1007\/s00198-008-0795-8 (2009).","journal-title":"Osteoporos. Int."},{"key":"4595_CR37","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1097\/MLR.0b013e31818afa1c","volume":"47","author":"JR Curtis","year":"2009","unstructured":"Curtis, J. R. et al. Improving the prediction of medication compliance: the example of bisphosphonates for osteoporosis. Med. Care. 47, 334\u2013341. https:\/\/doi.org\/10.1097\/MLR.0b013e31818afa1c (2009).","journal-title":"Med. Care"},{"key":"4595_CR38","doi-asserted-by":"publisher","first-page":"2721","DOI":"10.1007\/s00198-014-2810-6","volume":"25","author":"I Kyvernitakis","year":"2014","unstructured":"Kyvernitakis, I., Kostev, K., Kurth, A., Albert, U. S. & Hadji, P. Differences in persistency with teriparatide in patients with osteoporosis according to gender and health care provider. Osteoporos. Int. 25, 2721\u20132728. https:\/\/doi.org\/10.1007\/s00198-014-2810-6 (2014).","journal-title":"Osteoporos. Int."},{"key":"4595_CR39","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.1007\/s00198-021-05859-w","volume":"32","author":"CB Chang","year":"2021","unstructured":"Chang, C. B. et al. One-year outcomes of an osteoporosis liaison services program initiated within a healthcare system. Osteoporos. Int. 32, 2163\u20132172. https:\/\/doi.org\/10.1007\/s00198-021-05859-w (2021).","journal-title":"Osteoporos. Int."},{"key":"4595_CR40","doi-asserted-by":"publisher","first-page":"101068","DOI":"10.1016\/j.bonr.2021.101068","volume":"14","author":"T Kobayakawa","year":"2021","unstructured":"Kobayakawa, T. et al. Real-world effects and adverse events of Romosozumab in Japanese osteoporotic patients: A prospective cohort study. Bone Rep. 14, 101068. https:\/\/doi.org\/10.1016\/j.bonr.2021.101068 (2021).","journal-title":"Bone Rep."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-04595-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-04595-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-04595-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T23:12:39Z","timestamp":1751411559000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-04595-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,2]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4595"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-04595-z","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,2]]},"assertion":[{"value":"26 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was approved by Ditmanson Medical Foundation Chia-Yi Christian Hospital institutional review board (approval no. 2024056). Patient consent was waived by Ditmanson Medical Foundation Chia-Yi Christian Hospital institutional review board due to the retrospective study design.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}],"article-number":"22548"}}